After AstraZeneca’s acquisition of Amolyt made the Paris-based investment group a tidy profit, Andera spoke to Scrip about the rejuvenated investment market in Europe.

But the cash will probably not be enough to prove its lead compound’s efficacy for a severe form of Crohn’s disease.

Tim Knotnerus is empowering Agomab’s team to investigate the potential of growth factor pathways across four different fibrotic indications.

Private Company Edition: The amount of venture capital raised by biopharma firms fell but individual companies grabbed a lot of cash, making for a remarkable Q2 relative to pre-pandemic times. Recent Q3 rounds includes Frontera’s $160m series B. Also, Oxford Science Enterprises added €250m to its fund.